Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIOSKILL: Studying Vacc-4x, an HIV therapeutic vaccine, an assessment of immune-mediated anti-viral effects, when administered with adjuvant GM-CSF prior to HIV latent reservoir activation by the HDAC inhibitor, romidepsin

Next Previous
Search
Trial Profile

BIOSKILL: Studying Vacc-4x, an HIV therapeutic vaccine, an assessment of immune-mediated anti-viral effects, when administered with adjuvant GM-CSF prior to HIV latent reservoir activation by the HDAC inhibitor, romidepsin

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vacc-4x (Primary) ; Romidepsin
  • Indications HIV infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BIOSKILL
  • Sponsors Bionor Holding

    • Most Recent Events

    • 07 Aug 2019 Status changed from recruiting to completed.
    • 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
    • 13 Mar 2016 Status changed from planning to recruiting as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top